GlassScriptPhysician profile
Lily Yeh
NPI 1407958424
$6,249.27
in general payments reported to CMS, 2019-2025
25 companies · $941 in 2025
The $941 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $476 · 2021: $1,022 · 2022: $941 · 2023: $1,056 · 2024: $994 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $971.69 | 2022-2025 | Xiidra, Miebo, Infuse |
| Sun Pharmaceutical Industries INC. | $773.97 | 2019-2025 | Cequa |
| Alcon Vision LLC | $762.32 | 2019-2025 | Total30, Precision7, Tryptyr |
| Novartis Pharmaceuticals Corporation | $742.82 | 2019-2023 | |
| Coopervision INC. | $402.27 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $319.12 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $305.96 | 2019-2024 | Acuvue |
| Allergan, INC. | $299.52 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $292.12 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $213.78 | 2021-2022 | |
| Dompe US, INC. | $196.33 | 2022-2024 | Oxervate |
| Menicon America INC | $181.85 | 2019-2021 | |
| Oyster Point Pharma, INC. | $139.30 | 2023-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $130.35 | 2024-2025 | Vevye |
| Visioneering Technologies, INC. | $106.55 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $81.08 | 2019-2020 | |
| Shire North American Group INC | $71.34 | 2019 | |
| Abbvie INC. | $68.72 | 2022 | |
| Eyevance Pharmaceuticals LLC | $57.01 | 2022-2023 | Flarex |
| Thea Pharma INC. | $35.99 | 2023-2024 | Iyuzeh |
| Lombart Brothers, INC. | $24.69 | 2019 | |
| Akorn, INC. | $21.54 | 2020 | |
| Biotissue Holdings INC. | $21.01 | 2020 | |
| Abb Con-Cise Optical Group LLC | $15.01 | 2022 | |
| Aerie Pharmaceuticals, INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.